Familial mediterranean fever: Recent developments in pathogenesis and new recommendations for management

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Özen, Seza ^a   Batu, Ezgi Deniz ^a   Demir, Selcan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Colchicine; Familial Mediterranean fever; MEFV; Pyrin; Rho GTPases

Indexed keywords

ANAKINRA; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; PYRIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SERUM AMYLOID A;

AMYLOIDOSIS; APOPTOSIS; AUTOPHAGY; AUTOSOMAL RECESSIVE INHERITANCE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY ASSESSMENT; DRUG DOSE REDUCTION; EXTRACELLULAR TRAP; FAMILIAL MEDITERRANEAN FEVER; GASTROINTESTINAL SYMPTOM; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INFLAMMATION; MEFV GENE; PATIENT COMPLIANCE; PHENOTYPE; POLYSEROSITIS; PROTEIN MODIFICATION; RECOMMENDED DRUG DOSE; REFRACTORY PERIOD; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85017172373     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00253     Document Type: Review

References (139)

1. Daniels M, Shohat T, Brenner-Ullman A, Shohat M. Familial Mediterranean fever: high gene frequency among the non-Ashkenazic and Ashkenazic Jewish populations in Israel. Am J Med Genet (1995) 55(3):311-4. doi:10.1002/ajmg.1320550313
2. Ozen S, Karaaslan Y, Ozdemir O, Saatci U, Bakkaloglu A, Koroglu E, et al. Prevalence of juvenile chronic arthritis and familial Mediterranean fever in Turkey: a field study. J Rheumatol (1998) 25(12):2445-9
3. Kishida D, Nakamura A, Yazaki M, Tsuchiya-Suzuki A, Matsuda M, Ikeda SI. Genotype-phenotype correlation in Japanese patients with familial Mediterranean fever: differences in genotype and clinical features between Japanese and Mediterranean populations. Arthritis Res Ther (2014) 16(5):439. doi:10.1186/s13075-014-0439-7
4. Migita K, Agematsu K, Masumoto J, Ida H, Honda S, Jiuchi Y, et al. The contribution of SAA1 polymorphisms to familial Mediterranean fever susceptibility in the Japanese population. PLoS One (2013) 8(2):e55227. doi:10.1371/journal.pone.0055227
5. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (2005) 84(1):1-11. doi:10.1097/01.md.0000152370.84628.0c
6. Twig G, Livneh A, Vivante A, Afek A, Shamiss A, Derazne E, et al. Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis (2014) 73(4):704-9. doi:10.1136/annrheumdis-2012-202932
7. Sonmez HE, Batu ED, Bilginer Y, Ozen S. Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants. Clin Rheumatol (2016) 36(2):421-5. doi:10.1007/s10067-016-3421-8
8. Giancane G, Ter Haar N, Wulffraat N, Vastert B, Barron K, Hentgen V, et al. Evidence based recommendations for genetic diagnosis of familial Mediterranean fever. Pediatr Rheumatol Online J (2014) 12(Suppl 1):241. doi:10.1186/1546-0096-12-S1-P241
9. Aksentijevich I, Centola M, Deng Z, Sood R, Balow JE, Wood G, et al. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell (1997) 90(4):797-807. doi:10.1016/S0092-8674(00)80539-5
10. French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet (1997) 17(1):25-31. doi:10.1038/ng0997-25
11. Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum (2007) 37(3):182-8. doi:10.1016/j.semarthrit.2007.03.005
12. Xu H, Yang J, Gao W, Li L, Li P, Zhang L, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the pyrin inflammasome. Nature (2014) 513(7517):237-41. doi:10.1038/nature13449
13. Majeed HA, Rawashdeh M, el-Shanti H, Qubain H, Khuri-Bulos N, Shahin HM. Familial Mediterranean fever in children: the expanded clinical profile. QJM (1999) 92(6):309-18. doi:10.1093/qjmed/92.6.309
14. Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum (1991) 34(8):973-7. doi:10.1002/art.1780340806
15. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol (2000) 14(3):477-98. doi:10.1053/berh.2000.0089
16. Ben-Zvi I, Livneh A. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. Isr Med Assoc J (2014) 16(5):271-3
17. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis (2016) 75(4):644-51. doi:10.1136/annrheumdis-2015-208690
18. Stoffels M, Szperl A, Simon A, Netea MG, Plantinga TS, van Deuren M, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis (2014) 73(2):455-61. doi:10.1136/annrheumdis-2012-202580
19. Balow JE Jr, Shelton DA, Orsborn A, Mangelsdorf M, Aksentijevich I, Blake T, et al. A high-resolution genetic map of the familial Mediterranean fever candidate region allows identification of haplotype-sharing among ethnic groups. Genomics (1997) 44(3):280-91. doi:10.1006/geno.1997.4860
20. Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum (2009) 60(6):1851-61. doi:10.1002/art.24569
21. Shinar Y, Obici L, Aksentijevich I, Bennetts B, Austrup F, Ceccherini I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis (2012) 71(10):1599-605. doi:10.1136/annrheumdis-2011-201271
22. Moradian MM, Sarkisian T, Ajrapetyan H, Avanesian N. Genotype-phenotype studies in a large cohort of Armenian patients with familial Mediterranean fever suggest clinical disease with heterozygous MEFV mutations. J Hum Genet (2010) 55(6):389-93. doi:10.1038/jhg.2010.52
23. Sarkisian T, Ajrapetyan H, Shahsuvaryan G. Molecular study of FMF patients in Armenia. Curr Drug Targets Inflamm Allergy (2005) 4(1):113-6. doi:10.2174/1568010053622885
24. El-Shanti H, Majeed HA, El-Khateeb M. Familial Mediterranean fever in Arabs. Lancet (2006) 367(9515):1016-24. doi:10.1016/S0140-6736(06)68430-4
25. Padeh S, Shinar Y, Pras E, Zemer D, Langevitz P, Pras M, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with familial Mediterranean fever. J Rheumatol (2003) 30(1):185-90
26. Majeed HA, El-Shanti H, Al-Khateeb MS, Rabaiha ZA. Genotype/phenotype correlations in Arab patients with familial Mediterranean fever. Semin Arthritis Rheum (2002) 31(6):371-6. doi:10.1053/sarh.2002.32551
27. Ben-Chetrit E, Lerer I, Malamud E, Domingo C, Abeliovich D. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? Hum Mutat (2000) 15(4):385-6. doi:10.1002/(SICI)1098-1004(200004)15:4<385:AID-HUMU22>3.0.CO;2-A
28. Aksentijevich I, Torosyan Y, Samuels J, Centola M, Pras E, Chae JJ, et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet (1999) 64(4):949-62. doi:10.1086/302327
29. Bernot A, da Silva C, Petit JL, Cruaud C, Caloustian C, Castet V, et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). Hum Mol Genet (1998) 7(8):1317-25. doi:10.1093/hmg/7.8.1317
30. Ozen S, Batu ED. The myths we believed in familial Mediterranean fever: what have we learned in the past years? Semin Immunopathol (2015) 37(4):363-9. doi:10.1007/s00281-015-0484-6
31. Tchernitchko D, Legendre M, Cazeneuve C, Delahaye A, Niel F, Amselem S. The E148Q MEFV allele is not implicated in the development of familial Mediterranean fever. Hum Mutat (2003) 22(4):339-40. doi:10.1002/humu.9182
32. Topaloglu R, Ozaltin F, Yilmaz E, Ozen S, Balci B, Besbas N, et al. E148Q is a disease-causing MEFV mutation: a phenotypic evaluation in patients with familial Mediterranean fever. Ann Rheum Dis (2005) 64(5):750-2. doi:10.1136/ard.2004.026963
33. Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, et al. Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet (2001) 9(7):553-5. doi:10.1038/sj.ejhg.5200674
34. Topaloglu R, Batu ED, Yildiz C, Korkmaz E, Ozen S, Besbas N, et al. Familial Mediterranean fever patients homozygous for E148Q variant. Int J Rheum Dis (2016). doi:10.1111/1756-185X.12929
35. Cazeneuve C, Hovannesyan Z, Genevieve D, Hayrapetyan H, Papin S, Girodon-Boulandet E, et al. Familial Mediterranean fever among patients from Karabakh and the diagnostic value of MEFV gene analysis in all classically affected populations. Arthritis Rheum (2003) 48(8):2324-31. doi:10.1002/art.11102
36. Marek-Yagel D, Berkun Y, Padeh S, Abu A, Reznik-Wolf H, Livneh A, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum (2009) 60(6):1862-6. doi:10.1002/art.24570
37. Federici S, Calcagno G, Finetti M, Gallizzi R, Meini A, Vitale A, et al. Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum Dis (2012) 71(12):1961-5. doi:10.1136/annrheumdis-2011-200977
38. Niemi K, Teirila L, Lappalainen J, Rajamaki K, Baumann MH, Oorni K, et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol (2011) 186(11):6119-28. doi:10.4049/jimmunol.1002843
39. Atoyan S, Hayrapetyan H, Sarkisian T, Ben-Chetrit E. MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia. Clin Exp Rheumatol (2016) 34(6 Suppl 102):72-6
40. Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum (2007) 56(5):1706-12. doi:10.1002/art.22507
41. Ozen S, Demirkaya E, Amaryan G, Kone-Paut I, Polat A, Woo P, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis (2014) 73(4):662-7. doi:10.1136/annrheumdis-2012-202708
42. Aldea A, Campistol JM, Arostegui JI, Rius J, Maso M, Vives J, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? Am J Med Genet A (2004) 124A(1):67-73. doi:10.1002/ajmg.a.20296
43. Booth DR, Gillmore JD, Lachmann HJ, Booth SE, Bybee A, Soyturk M, et al. The genetic basis of autosomal dominant familial Mediterranean fever. QJM (2000) 93(4):217-21. doi:10.1093/qjmed/93.4.217
44. Fukushima Y, Obara K, Hirata H, Sugiyama K, Fukuda T, Takabe K. Three Japanese patients (mother and two children) with familial Mediterranean fever associated with compound heterozygosity for L110P/E148Q/M694I and an autosomal true dominant inheritance pattern. Asian Pac J Allergy Immunol (2013) 31(4):325-9. doi:10.12932/AP0244.31.4.2013
45. Rowczenio DM, Iancu DS, Trojer H, Gilbertson JA, Gillmore JD, Wechalekar AD, et al. Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic exploration. Rheumatology (2016) 56(2):209-13. doi:10.1093/rheumatology/kew058
46. Khachatryan ZA, Ktsoyan ZA, Manukyan GP, Kelly D, Ghazaryan KA, Aminov RI. Predominant role of host genetics in controlling the composition of gut microbiota. PLoS One (2008) 3(8):e3064. doi:10.1371/journal.pone.0003064
47. Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol (2012) 12(8):570-80. doi:10.1038/nri3261
48. Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ (2007) 14(8):1457-66. doi:10.1038/sj.cdd.4402142
49. Hesker PR, Nguyen M, Kovarova M, Ting JP, Koller BH. Genetic loss of murine pyrin, the familial Mediterranean fever protein, increases interleukin-1beta levels. PLoS One (2012) 7(11):e51105. doi:10.1371/journal.pone.0051105
50. Yu JW, Fernandes-Alnemri T, Datta P, Wu J, Juliana C, Solorzano L, et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell (2007) 28(2):214-27. doi:10.1016/j.molcel.2007.08.029
51. Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity (2011) 34(5):755-68. doi:10.1016/j.immuni.2011.02.020
52. Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol (2016) 17(8):914-21. doi:10.1038/ni.3457
53. Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol (2013) 13(5):321-35. doi:10.1038/nri3430
54. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature (2010) 467(7316):711-3. doi:10.1038/nature09397
55. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, et al. Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 458(7242):1176-9. doi:10.1038/nature07822
56. Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, et al. Non-canonical inflammasome activation targets caspase-11. Nature (2011) 479(7371):117-21. doi:10.1038/nature10558
57. Ng J, Hirota SA, Gross O, Li Y, Ulke-Lemee A, Potentier MS, et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology (2010) 139(2):e1-3. doi:10.1053/j.gastro.2010.04.005
58. Van Gorp H, Saavedra PH, de Vasconcelos NM, Van Opdenbosch N, Vande Walle L, Matusiak M, et al. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in pyrin inflammasome activation. Proc Natl Acad Sci U S A (2016) 113(50):14384-9. doi:10.1073/pnas.1613156113
59. Kimura T, Jain A, Choi SW, Mandell MA, Schroder K, Johansen T, et al. TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. J Cell Biol (2015) 210(6):973-89. doi:10.1083/jcb.201503023
60. Apostolidou E, Skendros P, Kambas K, Mitroulis I, Konstantinidis T, Chrysanthopoulou A, et al. Neutrophil extracellular traps regulate IL-1beta-mediated inflammation in familial Mediterranean fever. Ann Rheum Dis (2016) 75(1):269-77. doi:10.1136/annrheumdis-2014-205958
61. Gohar F, Orak B, Kallinich T, Jeske M, Lieber M, von Bernuth H, et al. Correlation of secretory activity of neutrophils with genotype in patients with familial Mediterranean fever. Arthritis Rheumatol (2016) 68(12):3010-22. doi:10.1002/art.39784
62. Manukyan G, Aminov R, Hakobyan G, Davtyan T. Accelerated apoptosis of neutrophils in familial Mediterranean fever. Front Immunol (2015) 6:239. doi:10.3389/fimmu.2015.00239
63. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med (1972) 287(25):1302. doi:10.1056/NEJM197212212872514
64. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature (2004) 428(6979):198-202. doi:10.1038/nature02393
65. Taskiran EZ, Cetinkaya A, Balci-Peynircioglu B, Akkaya YZ, Yilmaz E. The effect of colchicine on pyrin and pyrin interacting proteins. J Cell Biochem (2012) 113(11):3536-46. doi:10.1002/jcb.24231
66. Krendel M, Zenke FT, Bokoch GM. Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol (2002) 4(4):294-301. doi:10.1038/ncb773
67. Ben-Chetrit E, Bergmann S, Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (2006) 45(3):274-82. doi:10.1093/rheumatology/kei140
68. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy (2005) 4(1):117-24. doi:10.2174/1568010053622984
69. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther (2006) 8(Suppl 1):S3. doi:10.1186/ar1908
70. Manukyan G, Petrek M, Tomankova T, Martirosyan A, Tatyan M, Navratilova Z, et al. Colchicine modulates expression of pro-inflammatory genes in neutrophils from patients with familial Mediterranean fever and healthy subjects. J Biol Regul Homeost Agents (2013) 27(2):329-36
71. Ben-Chetrit E, Backenroth R. Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis (2001) 60(2):146-9. doi:10.1136/ard.60.2.146
72. Cazeneuve C, Sarkisian T, Pecheux C, Dervichian M, Nedelec B, Reinert P, et al. MEFV-gene analysis in armenian patients with familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet (1999) 65(1):88-97. doi:10.1086/302459
73. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum (2003) 48(4):1149-55. doi:10.1002/art.10944
74. Livneh A, Langevitz P, Shinar Y, Zaks N, Kastner DL, Pras M, et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid (1999) 6(1):1-6. doi:10.3109/13506129908993281
75. Medlej-Hashim M, Delague V, Chouery E, Salem N, Rawashdeh M, Lefranc G, et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet (2004) 5:4. doi:10.1186/1471-2350-5-4
76. Mimouni A, Magal N, Stoffman N, Shohat T, Minasian A, Krasnov M, et al. Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics (2000) 105(5):E70. doi:10.1542/peds.105.5.e70
77. Shohat M, Magal N, Shohat T, Chen X, Dagan T, Mimouni A, et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet (1999) 7(3):287-92. doi:10.1038/sj.ejhg.5200303
78. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum (2013) 43(3):387-91. doi:10.1016/j.semarthrit.2013.04.011
79. Polat A, Acikel C, Sozeri B, Dursun I, Kasapcopur O, Gulez N, et al. Comparison of the efficacy of once-and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever-a randomized controlled noninferiority trial. Arthritis Res Ther (2016) 18:85. doi:10.1186/s13075-016-0980-7
80. Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr (2012) 161(6):1142-6. doi:10.1016/j.jpeds.2012.05.047
81. Jayaprakash V, Ansell G, Galler D. Colchicine overdose: the devil is in the detail. N Z Med J (2007) 120(1248):U2402
82. Varughese GI, Varghese AI, Tahrani AA. Colchicine: time to rethink. N Z Med J (2007) 120(1249):U2429
83. Fradkin A, Yahav J, Zemer D, Jonas A. Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci (1995) 31(10):616-20
84. Mor A, Gal R, Livneh A. Abdominal and digestive system associations of familial Mediterranean fever. Am J Gastroenterol (2003) 98(12):2594-604. doi:10.1111/j.1572-0241.2003.08784.x
85. Batu ED, Arici ZS, Bilginer Y, özen S. Current therapeutic options for managing familial Mediterranean fever. Expert Opin Orphan Drugs (2015) 3(9):1063-73. doi:10.1517/21678707.2015.1073149
86. Ben-Chetrit E, Navon P. Colchicine-induced leukopenia in a patient with familial Mediterranean fever: the cause and a possible approach. Clin Exp Rheumatol (2003) 21(4 Suppl 30):S38-40
87. Choi SS, Chan KF, Ng HK, Mak WP. Colchicine-induced myopathy and neuropathy. Hong Kong Med J (1999) 5(2):204-7
88. Malkinson FD, Lynfield YL. Colchicine alopecia. J Invest Dermatol (1959) 33:371-84. doi:10.1038/jid.1959.162
89. Yilmaz ROS, Ozyurt H, Erkorkmaz U. Serum vitamin B12 status in children with familial Mediterranean fever receiving colchicine treatment. Hong Kong J Paediatr (2011) 16:3-8
90. Barsoum H. The effect of colchicine on the spermatogenesis of rabbits. J Pharmacol Exp Ther (1955) 115(3):319-22
91. Merlin HE. Azoospermia caused by colchicine-a case report. Fertil Steril (1972) 23(3):180-1. doi:10.1016/S0015-0282(16)38823-9
92. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics (2001) 108(3):776-89. doi:10.1542/peds.108.3.776
93. Ben-Chetrit E, Ben-Chetrit A, Berkun Y, Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res (2010) 62(2):143-8. doi:10.1002/acr.20061
94. Diav-Citrin O, Shechtman S, Schwartz V, Avgil-Tsadok M, Finkel-Pekarsky V, Wajnberg R, et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol (2010) 203(2):e1-6. doi:10.1016/j.ajog.2010.02.063
95. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (2010) 48(5):407-14. doi:10.3109/15563650.2010.495348
96. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med (1986) 314(16):1001-5. doi:10.1056/NEJM198604173141601
97. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 11(8):633-52. doi:10.1038/nrd3800
98. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 367(25):2396-406. doi:10.1056/NEJMoa1205099
99. van der Hilst J, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics (2016) 10:75-80. doi:10.2147/BTT.S102954
100. Brik R, Butbul-Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz-Minei T, Tseng L, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol (2014) 66(11):3241-3. doi:10.1002/art.38777
101. Gul A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther (2015) 17:243. doi:10.1186/s13075-015-0765-4
102. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or-intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med (2012) 157(8):533-41. doi:10.7326/0003-4819-157-8-201210160-00003
103. Alpay N, Sumnu A, Caliskan Y, Yazici H, Turkmen A, Gul A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int (2012) 32(10):3277-9. doi:10.1007/s00296-010-1474-6
104. Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med (2007) 146(11):825-6. doi:10.7326/0003-4819-146-11-200706050-00023
105. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr (2008) 167(6):695-6. doi:10.1007/s00431-007-0547-3
106. Celebi ZK, Kucuksahin O, Sengul S, Tuzuner A, Keven K. Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra. Clin Kidney J (2014) 7(2):219-20. doi:10.1093/ckj/sft164
107. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A (2006) 103(26):9982-7. doi:10.1073/pnas.0602081103
108. Estublier C, Stankovic Stojanovic K, Bergerot JF, Broussolle C, Seve P. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine (2013) 80(6):645-9. doi:10.1016/j.jbspin.2013.03.004
109. Gattringer R, Lagler H, Gattringer KB, Knapp S, Burgmann H, Winkler S, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest (2007) 37(11):912-4. doi:10.1111/j.1365-2362.2007.01868.x
110. Hennig S, Bayegan K, Uffmann M, Thalhammer F, Winkler S. Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review. Rheumatol Int (2012) 32(6):1801-4. doi:10.1007/s00296-010-1429-y
111. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis (2007) 66(11):1545-6. doi:10.1136/ard.2007.071498
112. Mercan R, Turan A, Bitik B, Tufan A, Haznedaroglu S, Goker B. Rapid resolution of protracted febrile myalgia syndrome with anakinra: report of two cases. Mod Rheumatol (2016) 26(3):458-9. doi:10.3109/14397595.2014.882221
113. Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med (2008) 66(11):489-91
114. Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant (2009) 24(2):676-8. doi:10.1093/ndt/gfn646
115. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol (2011) 38(3):516-8. doi:10.3899/jrheum.100718
116. Petropoulou AD, Robin M, Socie G, Galicier L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation (2010) 90(1):102-3. doi:10.1097/TP.0b013e3181d84cc3
117. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine (2008) 75(4):504-5. doi:10.1016/j.jbspin.2008.04.001
118. Sevillano AM, Hernandez E, Gonzalez E, Mateo I, Gutierrez E, Morales E, et al. Anakinra induces complete remission of nephrotic syndrome in a patient with familial mediterranean fever and amyloidosis. Nefrologia (2016) 36(1):63-6. doi:10.1016/j.nefro.2015.06.026
119. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1beta biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol (2013) 45(1):117-30. doi:10.1007/s12016-013-8358-y
120. Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jeru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant (2012) 27(5):1898-901. doi:10.1093/ndt/gfr528
121. Alpa M, Roccatello D. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther (2015) 9:1983-7. doi:10.2147/DDDT.S69117
122. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis (2011) 70(7):1347-8. doi:10.1136/ard.2010.146878
123. Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, et al. Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever. Inflammation (2015) 38(1):27-31. doi:10.1007/s10753-014-0004-1
124. Eroglu FK, Besbas N, Topaloglu R, Ozen S. Treatment of colchicine-resistant familial Mediterranean fever in children and adolescents. Rheumatol Int (2015) 35(10):1733-7. doi:10.1007/s00296-015-3293-2
125. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum (2011) 41(2):265-71. doi:10.1016/j.semarthrit.2010.11.003
126. Ozcakar ZB, Ozdel S, Yilmaz S, Kurt-Sukur ED, Ekim M, Yalcinkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol (2016) 35(2):441-6. doi:10.1007/s10067-014-2772-2
127. Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol (2016) 31(4):633-40. doi:10.1007/s00467-015-3249-5
128. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis (2011) 70(12):2155-8. doi:10.1136/ard.2011.149922
129. Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol (2011) 17(7):358-62. doi:10.1097/RHU.0b013e31823682f5
130. Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol (2006) 24(5 Suppl 42):S99-103
131. Kaplan E, Mukamel M, Barash J, Brik R, Padeh S, Berkun Y, et al. Protracted febrile myalgia in children and young adults with familial Mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis. Clin Exp Rheumatol (2007) 25(4 Suppl 45):S114-7
132. Sidi G, Shinar Y, Livneh A, Langevitz P, Pras M, Pras E. Protracted febrile myalgia of familial Mediterranean fever. Mutation analysis and clinical correlations. Scand J Rheumatol (2000) 29(3):174-6. doi:10.1080/030097400750002058
133. Langevitz P, Zemer D, Livneh A, Shemer J, Pras M. Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol (1994) 21(9):1708-9
134. Majeed HA, Al-Qudah AK, Qubain H, Shahin HM. The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum (2000) 30(2):138-43. doi:10.1053/sarh.2000.16646
135. Ozen S. Changing concepts in familial Mediterranean fever: is it possible to have an autosomal-recessive disease with only one mutation? Arthritis Rheum (2009) 60(6):1575-7. doi:10.1002/art.24565
136. Ben-Zvi I, Krichely-Vachdi T, Feld O, Lidar M, Kivity S, Livneh A. Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study. Orphanet J Rare Dis (2014) 9:3. doi:10.1186/1750-1172-9-3
137. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis (2014) 73(5):897-901. doi:10.1136/annrheumdis-2013-204719
138. Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis (2014) 73(12):2168-73. doi:10.1136/annrheumdis-2013-203666
139. Ter Haar NM, Annink KV, Al-Mayouf SM, Amaryan G, Anton J, Barron KS, et al. Development of the autoinflammatory disease damage index (ADDI). Ann Rheum Dis (2016). doi:10.1136/annrheumdis-2016-210092